The ACGME-accredited Hematopathology Fellowship Program at Roswell Park provides fellows with an immersive training experience in all aspects of diagnostic hematopathology. Fellows will be working in very active clinical and consultation services with sub-specialized hematopathologists dedicated to education. Supporting a busy hematology/oncology service in Upstate New York’s only National Cancer Institute (NCI)-designated comprehensive cancer center, fellows will quickly develop critical skills necessary for careers in academia or community practice.
Fellows will practice integrated diagnosis by incorporating flow cytometric, cytogenetic, and molecular results with morphologic findings. The fellows will also participate in various clinical and educational activities, including consensus conferences, tumor boards, journal clubs, didactic lectures, educational conferences, and research projects. We foster a supportive environment deeply committed to diversity and inclusion.
Stipends are commensurate with a postgraduate year of training. Fellows also receive funds for educational resources and professional development.
Eligibility & how to apply
- You must complete your residency training in an ACGME-accredited program (or Canadian equivalent) prior to your fellowship start date.
- You must be eligible for a New York State Medical License or Limited Permit.
To apply, send your CV, fellowship application form, a personal statement, and three letters of reference to Danielle.Selleck@RoswellPark.org.
- Torka P, Groman A, Wong J, Baysal B, Nichols J, Kader A, Mavis C, Sait SJ, Block A, Przespolewski E, Mohr A, Lund I, McWhite K, Kostrewa J, DeMarco J, Johnson M, Darrall A, Thomas R, Sundaram S, Ghione P, Hutson A, Hernandez-Ilizaliturri FJ. Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory DLBCL. Blood advances. 2022; [in press].
- Merz M, Qiang H, Merz AMA, Wang J, Hutson N, Rondeau C, Celotto K, Belal A, Alberico R, Block AW, Mohammadpour H, Wallace PK, Tario J, Luce J, Glenn ST, Singh P, Samur M, Munshi N, Liu S, McCarthy PL, Wei L, Hillengass J. Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma. Blood Advances. 2022 Jul 22; Online ahead of print. PMID 35868022.
- Torka P, Akhtar O, Reddy N, Baysal B, Kader A, Groman A, Nichols J, Mavis C, Tario J, Block A, Sait S, Ghione P, Sundaram S, Przespolewski E, Mohr A, Lund I, Kostrewa J, McWhite K, DeMarco J, Johnson M, Darrall A, Thomas-Talley R, Wallace P, Nepalli V, Hutson A, Hernandez-Ilizaliturri F. Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study. Cancer. 2022 Apr 15; 128(8): 1595-1604. PMID 35157306.
- Ali SF, Cloe A, Siaghani PJ, Himchak E, Cantu D, Gaal K, Kim YS, Afkhami M, Pillai R, Chan W, Quirk E, Weisenburger DD, Aoun P, Song JY. Bone Marrow Collection: Comparison of Unassisted vs Assisted Bedside Collections by a Laboratory Technologist. Am J Clin Pathol. 2022 Apr 1;157(4):573-577. doi: 10.1093/ajcp/aqab165. PMID: 34788366.
- Merz M, Merz AMA, Wang J, Wei L, Hu Q, Hutson N, Rondeau C, Celotto K, Belal A, Alberico R, Block AW, Mohammadpour H, Wallace PK, Tario J, Luce J, Glenn ST, Singh P, Herr MM, Hahn T, Samur M, Munshi N, Liu S, McCarthy PL, Hillengass J. Deciphering spatial heterogeneity at single cell resolution in multiple myeloma. Nature Communications. 2022 Feb 10; 13(1): 807. PMID 35145077.
- Ramis-Zaldivar JE, Gonzalez-Farre B, Nicolae A, Pack S, Clot G, Nadeu F, Mottok A, Horn H, Song JY, Fu K, Wright G, Gascoyne RD, Chan WC, Scott DW, Feldman AL, Valera A, Enjuanes A, Braziel RM, Smeland EB, Staudt LM, Rosenwald A, Rimsza LM, Ott G, Jaffe ES, Salaverria I, Campo E. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica. 2021 Oct 1;106(10):2682-2693. PMID: 33951889.
- Li P, Yuan J, Ahmed FS, McHenry A, Fu K, Yu G, Cheng H, Xu ML, Rimm DL, Pan Z. High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated with Inferior Prognosis. Front Oncol. 2021 Aug 30;11:701492. eCollection 2021. PMID: 34527580.
- Li Y, Fei Y, Liu L, Song Z, Meng X, Qiu L, Li L, Qian Z, Zhou S, Ren X, Bi C, Meng B, Zhang H, Wang X, Fu K. Programmed Cell Death Protein 1/Programmed Cell Death Ligand-1 Axis activates Intracellular ERK Signaling in Tumor Cells to Mediate Poor Prognosis in T-cell Lymphoma. J Cancer. 2021 Aug 25;12(20):6126-6134. eCollection 2021. PMID: 34539885.
- Chaudhary S, Brown N, Song JY, Yang L, Skrabek P, Nasr MR, Wong JT, et al. Relative frequency and clinicopathologic characteristics of MYC-rearranged follicular lymphoma. Human Pathology. 2021 Aug;114:19-27. PMID: 33964277.
- Wang C, Althof PA, Bi C, Zhang W, Bouska AC, Tian T, Zhang X, Jiang N, Yu G, Cheng H, Iqbal J, Vose JM, Sanmann JN, Fu K. A novel MYC-non-IG fusion in refractory diffuse large B-cell lymphoma. Br J Haematol. 2021 Jun;193(5):1001-1004. PMID: 33942298.
- Veronica Ortega; Christina Mendiola; Juana Rodriguez; William Ehman Jr.; You-Wen Qian; Gopalrao Velagaleti. Bi-allelic Amplification of ATM Gene in Blastoid Variant of Mantle Cell Lymphoma: A Novel Mechanism of Inactivation due to Chromoanagenesis? Mol Cytogenet. 2021 Feb 4;14(1):8. PMID: 33541390.